References
Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.JAMA . 2021 Jan 21. doi: 10.1001/jama.2021.0600. Epub ahead of print. PMID: 33475702.
Center for Disease Control and Prevention. Allergic Reactions Including Anaphylaxis After
Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm Accessed 17.02.2021.
  1. Caballero ML, Quirce S. Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of the current authorized COVID-19 vaccines. J Investig Allergol Clin Immunol. 2021 Jan 12:0. doi: 10.18176/jiaci.0667. Epub ahead of print. PMID: 33433387.
  2. Sokolowska M, Eiwegger T, Ollert M, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy . 2021 Jan 16. doi: 10.1111/all.14739. Epub ahead of print. PMID: 33452689.
  3. Worm M, Bauer A, Wedi B, et al. Practical recommendations for the allergological risk assessment of the COVID-19 vaccination - a harmonized statement of allergy centers in Germany. Allergol Select. 2021 Jan 26;5:72-76. doi: 10.5414/ALX02225E. PMID: 33521511; PMCID: PMC7841415.
  4. Stingeni L, Bianchi L, Tramontana M, et al. Skin tests in the diagnosis of adverse drug reactions. G Ital Dermatol Venereol.2020;155(5):602-621.
  5. Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702-712.
TABLE 1 Patients characteristic and adverse mucous-cutaneous reactions in 6 patients after the first dose of Pfizer-BioNTech vaccine.